United Capital Financial Advisors LLC Invests $272,000 in argenx SE (NASDAQ:ARGX)

United Capital Financial Advisors LLC bought a new position in shares of argenx SE (NASDAQ:ARGX - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 443 shares of the company's stock, valued at approximately $272,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC grew its stake in argenx by 5.6% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company's stock valued at $234,000 after acquiring an additional 20 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company's stock worth $220,000 after acquiring an additional 21 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock valued at $47,000 after purchasing an additional 21 shares during the last quarter. Dynasty Wealth Management LLC grew its position in argenx by 3.4% during the fourth quarter. Dynasty Wealth Management LLC now owns 677 shares of the company's stock valued at $416,000 after acquiring an additional 22 shares during the period. Finally, Choreo LLC increased its position in argenx by 4.4% during the 4th quarter. Choreo LLC now owns 551 shares of the company's stock worth $342,000 after purchasing an additional 23 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ARGX. JMP Securities increased their target price on argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a research note on Tuesday, January 14th. William Blair reaffirmed an "outperform" rating on shares of argenx in a research report on Friday, February 28th. Piper Sandler boosted their target price on shares of argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a research note on Tuesday, January 7th. Sanford C. Bernstein upgraded argenx from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. Finally, Citigroup lifted their price objective on shares of argenx from $681.00 to $796.00 and gave the company a "buy" rating in a research report on Thursday, April 17th. Three research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $699.28.

argenx Stock Up 2.4 %

argenx stock traded up $14.25 during midday trading on Friday, hitting $614.76. 215,836 shares of the stock were exchanged, compared to its average volume of 308,025. The stock has a market capitalization of $37.54 billion, a PE ratio of -698.59 and a beta of 0.60. argenx SE has a 52 week low of $352.77 and a 52 week high of $678.21. The company has a fifty day simple moving average of $598.28 and a two-hundred day simple moving average of $607.83.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million during the quarter, compared to analysts' expectations of $678.52 million. As a group, equities research analysts anticipate that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.